Uterine Serous Carcinoma Completed Phase 2 Trials for Adavosertib (DB11740)

IndicationStatusPhase
DBCOND0122528 (Uterine Serous Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04590248A Study of Adavosertib as Treatment for Uterine Serous CarcinomaTreatment